Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P.
Chemioterapia International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
1984
ISSN/ISBN: 0392-906X PMID: 6241848 Document Number: 227447
Twenty-six patients with metastatic breast cancer were treated with high dose medroxyprogesterone acetate (MAP) p.o. according to currently available pharmacokinetic data (2000 mg/day b.i.d. for 30 days, 1000 mg/day for the following 60 days). Objective response (WHO criteria) was obtained in seven patients (CR + PR = 27%), with good results on visceral and soft tissue localizations; performance status improvement and/or pain relief was obtained in twenty-three (88%). Oral high dose MPA seems to be an effective and well tolerated palliative treatment in advanced breast cancer.